Navigation Links
United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStem's Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com
Date:10/7/2009

statements include the "Risk Factors" described in the Company's Registration Statement on Form S-4/A filed with the Commission on October 6, 2009 as well as periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Additional Information about the Merger and Where to Find It

NeoStem recently filed a Proxy Statement/Registration Statement with the SEC with respect to the shares of NeoStem Common Stock to be issued in connection with the Merger. Investors and security holders are advised to read the Proxy Statement/Registration Statement because it contains important information about NeoStem, China Biopharmaceuticals (CBH), the proposed Merger and other related matters. The final Proxy Statement/Registration Statement will be sent to stockholders of NeoStem seeking their approval of the proposed transaction. Investors and security holders will be able to obtain the documents free of charge at the SEC's web site, http://www.sec.gov. Since such final documents are not currently available, NeoStem's stockholders will receive information at an appropriate time as to how to obtain transaction-related documents free of charge from NeoStem.

This press release may be deemed to be solicitation material in respect of the proposed Merger. The directors and executive officers of each of NeoStem and CBH may be deemed to be participants in the solicitation of proxies from the holders of NeoStem Common Stock in respect of the proposed transaction. Information about the directors and executive officers of NeoStem is set forth in NeoStem's Proxy Statement for its 2009 Annual Meeting of Stockholders filed with the SEC on April 14, 2009 and in subsequent Forms 8-K. Investors may obtain additional information regarding the interest of N
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
2. Masimo Radical-7(R) and Rad-57(R) Pulse CO-Oximeters(TM) Awarded Airworthiness Release Certification by the United States Army
3. United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend
4. Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
5. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
6. Wyeth Provides Regulatory Update on Prevnar 13* in the United States
7. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
8. United States FDA Clears the REGEN Trial to Test Biohearts Combination Gene and Stem Cell Therapy in Heart Failure Patients
9. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
10. LS9's UltraClean Diesel Exceeds United States & Brazilian Fuels Specifications
11. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study ... from future storm surge flooding, such as occurred in Hurricane Ike in 2008. ... providing protection, Costello also balanced socio-economic and environmental needs and concerns. The ...
(Date:7/28/2015)... , July 29, 2015 ... acquiring, rapidly developing and commercialising innovative ... health   Highly experienced management team; blue ...   Mereo BioPharma Group Ltd ("Mereo"), ... raised $119m ( c. £76.5m), gross, from blue chip ...
(Date:7/28/2015)... 28, 2015 People with a common form ... significant and sometimes profound improvements in their hearing and ... to a new multicenter study led by specialists at ... described online ahead of print in the journal The Laryngoscope ... clinics in the United States ...
(Date:7/28/2015)... July 21, 2015 Research and Markets ... the "Biomedical Refrigerators and Freezers Market - ... Forecast 2014 - 2022" report to their ... and freezers market has been segmented based on ... banks, and others. The others segment includes applications ...
Breaking Biology Technology:Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3
... For 65 years, Mission Pharmacal Company has remained ... to provide the highest quality healthcare medications and treatments ... to be uncertain, this Texas-based company remains steadfast in ... to search for more and better prescription and consumer ...
... Fuels, Inc., (Pink Sheets: HRID ) announced ... CEO and President.  Mr. Cadena was the founder and ... Solutions, and will be instrumental in implementing the Company,s ... Mr. Cadena has over 25 years of extensive ...
... Md., Dec. 6, 2011 GenVec, Inc. (Nasdaq: ... the second milestone in its collaboration with Novartis (NYSE: ... treatments for hearing loss and balance disorders. The milestone ... development activities. "Completing this milestone reflects ...
Cached Biology Technology:Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 2Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 3Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 4Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 5Celebrating 65 Years of Providing Superior Healthcare Products, Mission Pharmacal Continues to Thrive 6Hybrid Fuels, Inc. Appoints Industry Expert as New CEO 2GenVec Achieves Second Milestone in Collaboration 2GenVec Achieves Second Milestone in Collaboration 3
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
(Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... new type of electrical generator uses bacterial spores to ... research conducted at the Wyss Institute of Biologically Inspired ... driven by changes in humidity from sun-warmed ponds and ... movement of a sheet of rubber coated on one ...
... study by Yale School of Medicine researchers provides insight into ... know about reproductive health. Published in the Jan. 27 issue ... about 50% of reproductive-age women had never discussed their reproductive ... reproductive health provider less than once a year or never. ...
... January 27, 2014 Cancer is the leading ... about 30% of all deaths, according to the Canadian ... effective drugs, it remains extremely difficult to develop anti-cancer ... at how to leverage current experimental therapies, in different ...
Cached Biology News:Getting a charge from changes in humidity 2Getting a charge from changes in humidity 3The science of baby-making still a mystery for many women 2Ottawa researchers discover new combination therapy to kill cancer 2
Rab GDP dissociation inhibitor beta...
... 500V Programmable Power Supply are high-performance, ... handle virtually any application from high ... It is unique in offering both ... POWER Programmable Power Supply is completely ...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
Biology Products: